The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has shown dramatic effects in patients with non-small cell lung cancer (NSCLC) harboring ROS1 fusion genes. However, patients inevitably develop resistance to this agent. Therefore, a new treatment strategy is required for lung tumors with ROS1 fusion genes. In the present study, lung 
| INTRODUCTION
The discovery of oncogenic driver genes and corresponding targeted drugs has changed the clinical treatment of non-small cell lung cancer (NSCLC) over the past 15 years. [1] [2] [3] Fusions in c-ros oncogene 1 (ROS1) have been identified in approximately 1%-2% of patients. 3, 4 ALK tyrosine kinase inhibitors (TKI, including crizotinib), which have been approved for clinical use, showed inhibitory activity against ROS1 because ROS1 and ALK protein share 49% amino acid sequence identity in their kinase domains. 5 The MET/ALK/ROS1 inhibitor crizotinib has been approved for clinical use as an inhibitor of ROS1 in several countries because it confers excellent benefits and shows acceptable tolerance in patients with ROS1 fusion-positive lung cancer. 6, 7 Similar to other oncoprotein inhibitors, however, lung tumors with ROS1 fusion genes inevitably acquire resistance to crizotinib, and further improvements in treatment strategies are, thus, required. 8 Many groups have explored the resistance mechanisms in lung tumors with ROS1 fusion genes in attempts to develop new treatment strategies. Similar to the mechanisms of resistance in lung cancers with ALK fusion genes, secondary mutations in the ROS1 kinase domain (eg, G2032R, S1986Y, S1986F, D2033N or L2155S) have been reported. [8] [9] [10] [11] However, the resistance mechanisms of ROS1
inhibitors have not been fully clarified in NSCLC harboring ROS1 fusion genes.
To develop a new treatment strategy for lung cancer patients with ROS1 fusion, we investigated the mechanisms of resistance to crizotinib using HCC78 cells harboring the SLC34A2-ROS1 fusion gene and the newly established lung cancer cell line, ABC-20 harboring the CD74-ROS1 fusion gene. Our analyses indicated that HB-EGF/epidermal growth factor receptor (EGFR) and AXL were attributable to the acquired resistance to crizotinib, and the combination of cabozantinib and gefitinib showed beneficial effects in crizotinibresistant cell lines both in vitro and in vivo. supplemented with 10% heat-inactivated FBS and 1% penicillin/ streptomycin in a tissue culture incubator at 37°C with 5% CO 2 .
| MATERIALS AND METHODS

|
To establish a crizotinib-resistant cell line, HCC78 cells were trea- 
| MTT assay
Growth inhibition was determined using a modified MTT assay. 
| Fluorescence in situ hybridization
FISH was performed on formalin-fixed, paraffin-embedded samples using a custom ROS1 break-apart probe set in the laboratory of SRL (Tokyo, Japan). 13 The probe set hybridizes with the neighboring 5′ 
| Statistical analysis
All experiments were performed 3 times, and statistical analyses were performed using STATA software (ver. 13; StataCorp, College Station, TX, USA). Group differences were compared using a 2-tailed unpaired t test. In the box plots, the center line is the median and whiskers show minimum to maximum values. In all analyses, P < .05 was considered to indicate statistical significance.
| RESULTS
| Epidermal growth factor receptor activation in crizotinib-resistant HCC78R cells
To explore the mechanisms of resistance, we used HCC78 cells Table 1 ). The ALK/EGFR inhibitor brigatinib exhibited a relatively good inhibitory effect in the resistant cells ( Figure 1E , Table 1 ). None of the HCC78R cell lines possessed acquired resistance mutations, such as ROS1 S1986Y, S1986F, D2033N or G2032R, in the ROS1 kinase domain [8] [9] [10] [11] (Figures S1D, Figure 1D ).
Taken together, these observations suggested that EGFR or AXL may play a role in the mechanism of resistance in HCC78R cells.
| Effects of epidermal growth factor receptor inhibitors in HCC78R
We performed an MTT assay using the EGFR-TKI (gefitinib) in HCC78R cells to examine whether activation of EGFR is responsible for crizotinib resistance. Gefitinib monotherapy had little effect on cell proliferation but co-treatment with gefitinib and crizotinib showed a superior effect of inhibiting the proliferation of parental HCC78 cells ( Figure S4B ). The results indicated that the EGFR pathway played an important role in intrinsic sensitivity to crizotinib in HCC78 cells. This was consistent with previous reports. 15, 16 In contrast to parental HCC78 cells, crizotinib showed no inhibitory effect ( Figure 1A ), but gefitinib inhibited the proliferation of HCC78R cells (IC 50 ± SD:
.136 ± .022 μmol/L) ( Figure 2A ). Next, we assessed the effects of EGFR-TKI on the EGFR signaling pathway in each cell line. Phosphorylation of EGFR and its downstream signaling protein, ERK1/2, was not suppressed in HCC78R cells treated with crizotinib, while these signaling pathways were suppressed upon gefitinib exposure ( Figure 2B ).
Adding gefitinib to crizotinib monotherapy showed a great inhibitory effect on the proliferation of HCC78R cells ( Figure S4C ). In contrast, combination therapy with gefitinib plus crizotinib was not superior to gefitinib monotherapy with regard to the proliferation of HCC78R
( Figure 2C ). These results suggested that the resistant HCC78R cells were no longer addicted to the oncogenic ROS1 fusion protein but were instead addicted to EGFR. To confirm the effect of EGFR-TKI, we performed the same experiments using other EGFR-TKI, erlotinib and afatinib. As expected, similar results were observed with both of these agents in HCC78R cells ( Figures S2A,B) . Third, we examined the inhibitory effect of the anti-EGFR antibody cetuximab, in vitro. Interestingly, cetuximab inhibited the proliferation of resistant cell lines to a significantly greater extent than that of the parental cells in vitro (mean IC 50 ± SD > 20 μg/mL for HCC78 cells and 11.2 ± 1.33 μg/mL for HCC78R cells ( Figure 2D ). Western blotting analysis showed that 1 or 5 μg/mL of cetuximab inhibited the phosphorylation of EGFR and its downstream signaling proteins ( Figure 2E ). Taken together, these observations suggested that the EGFR signaling pathway played an important role in the mechanism of resistance in HCC78R cells. Western blotting analysis indicated that the expression of total EGFR protein decreased, but the phosphorylation of EGFR and its downstream signaling protein, ERK1/2, was maintained under crizotinib exposure by the addition of HB-EGF to HCC78 cells (Figure 3D ). We also examined the effect of the conditioned medium prepared by mixing equal parts fresh medium and the supernatant of HCC78R cells. As expected, the conditioned medium rendered the parental HCC78 cells resistant to crizotinib in vitro ( Figure S3E ). In addition, we investigated the impact of other growth factors on the sensitivity of HCC78 cells to crizotinib. Consistent with the results for HB-EGF ( Figure 3C ), EGF (100 ng/mL) stimulation rendered HCC78 cells resistant to crizotinib in vitro ( Figure S3A ). Similar to the effects of HB-EGF, EGF maintained phosphorylation of EGFR and ERK1/2 in HCC78 treated with crizotinib ( Figure S3B ). In contrast to the results for EGFR ligand, neither insulin-like growth factor The antiproliferative effects were evaluated using the MTT assay. Data are presented as the mean ± SD from 3 independent experiments.
(IGF) nor fibroblast growth factor (FGF) rescued the proliferation of 
| AXL upregulation and resistance to crizotinib in HCC78R cells
To explore the mechanisms of resistance in more detail, we performed RNA-targeted sequence analysis using next-generation sequencing in HCC78 and HCC78R cells. The samples were collected from dishes in which HCC78 cells (n = 4) or HCC78R cells (n = 4) were independently cultured. The mRNA expression level of 612 human kinome genes and kinase-related genes was comprehensively compared ( Figure 4A ). The raw data are shown in Table S1 . cabozantinib 18 and gilteritinib, 19 were assessed in HCC78R cells.
F I G U R E 2 Effects of epidermal growth factor receptor (EGFR) inhibitor treatment in HCC78R cells. A, Cell proliferation assays in HCC78
and HCC78R cells treated with the indicated concentrations of gefitinib. Error bars: SD. All experiments were performed in triplicate. B, Effects of combined treatment with crizotinib and gefitinib on the EGFR signaling pathway in HCC78R cells. Cells were exposed to gefitinib at .5 μmol/L for 6 h, and crizotinib at .1 and .5 μmol/L for 6 h. C, Inhibitory effects of crizotinib and gefitinib on HCC78R cell proliferation upon the addition of .5 μmol/L crizotinib. Error bars: SD. All experiments were performed in triplicate. D, Cell proliferation assays in HCC78 and HCC78R cells treated with the indicated concentrations of cetuximab. Error bars: SD. All experiments were performed in triplicate. E, Effects of cetuximab on the EGFR pathway in HCC78R cells. Cells were exposed to cetuximab at 1 and 5 μg/mL for 6 h Compared with the effects of the EGFR-TKI gefitinib, the effects of cabozantinib and gilteritinib were relatively limited in HCC78R cells ( Figure 5A ). Furthermore, the combination of crizotinib with cabozantinib showed an antagonistic effect. In contrast, the combination of gefitinib with cabozantinib or gilteritinib inhibited cell proliferation to a significantly greater extent than gefitinib monotherapy ( Figure 5A ). Consistent with these observations, combination therapy more strongly inhibited phosphorylation of ERK1/2 than monotherapy ( Figure 5B ). In addition, we assessed the effect of combining gefitinib with knockdown of AXL using siRNA. As expected, the combination showed a superior inhibitory effect on cell proliferation than AXL inhibition alone in HCC78R cells ( Figure S7 ). Finally, we exam- Xenograft tumors treated with vehicle or crizotinib showed similar growth ( Figure 5C ), while cabozantinib showed a moderate effect on tumor growth in vivo. In contrast, gefitinib led to a significant inhibition of tumors in the mice. Combination therapy with gefitinib and cabozantinib also showed a better inhibitory effect than each of the monotherapies alone in mouse tumors bearing HCC78R cells, although this effect was not statistically significant ( Figure 5C ). No differences in body weight were observed among any of the mouse groups ( Figure 5C ).
| DISCUSSION
The development of resistance to targeted therapy is critical for patients with lung cancers harboring driver oncogenes. We demonstrated that HB-EGF/EGFR and AXL play roles in the mechanism of resistance of lung cancers harboring ROS1 fusions treated with crizotinib. Using a cell line-based model, we also found that dual inhibition of EGFR and AXL has the potential to overcome crizotinib resistance in vitro and in vivo. These findings could be clinically rele- 20, 21 Up to 50% of lung tumors harboring ROS1 fusion genes treated with crizotinib develop a secondary mutation, ROS1 G2032R, in the kinase domain. 8 Several next-generation ROS1 inhibitors have been developed for patients with lung cancers harboring ROS1 fusion genes. 22 Preclinical studies showed that lorlatinib, foretinib and cabozantinib can inhibit drug resistance. [23] [24] [25] The MET/VEGFR2/RET/ ROS1/AXL inhibitor, cabozantinib, has already been approved for use in patients with advanced renal cell carcinoma, and clinical trials have been conducted for lung cancer with RET gene fusion 26 or ROS1 fusion genes (NCT01639508). Therefore, cabozantinib could be a clinically relevant drug to overcome crizotinib resistance in lung cancers containing ROS1 fusion genes.
In addition to acquired mutations in the ROS1 kinase domain, activation of bypass track signaling, such as the EGFR, HER2, KIT, β-catenin or BRAF pathways, was reported as a mechanism of resistance against crizotinib. 9, [27] [28] [29] [30] Several preclinical studies, including our study, showed that stimulation of EGFR by EGF or HB-EGF resulted in resistance in multiple lung cancer cell lines harboring ROS1 fusions; ie, HCC78 with SLC34A2-ROS1, CUTO-2, and ABC-20 with CD74-ROS1. In addition, a recent preclinical study showed that inhibiting oncogenic fusion proteins, such as ALK, ROS1 and RET, induced a shift in the adaptor protein, GRB2, from the fusion oncoprotein to EGFR, resulting in activation of bypass track EGFR signaling. 16 We also showed that IGF and FGF did not affect crizotinib sensitivity in HCC78 cells ( Figure S3F ). Therefore, the EGFR pathway may be especially important for persister cells to survive drug exposure in lung cancer cells harboring ROS1 fusion genes.
In this study, we found that the AXL RNA expression level significantly increased in crizotinib-resistant HCC78R cells. AXL is thought to play a role in acquired resistance to oncoprotein inhibitors, [31] [32] [33] but its role regarding crizotinib resistance has not yet been reported.
We examined the effects of 2 clinically relevant AXL inhibitors in HCC78R cells. Monotherapy with AXL inhibitors showed only moderate effects, but combining AXL inhibitors with EGFR-TKI resulted in a superior inhibitory effect compared with monotherapies. This suggested that AXL plays some role, in concert with EGFR, in resistance to crizotinib.
"Oncogene swap" has been reported as a resistance mechanism in lung cancer with EGFR mutations. 34 In this situation, the activation of other oncogenes acts not as a "bypass", but rather as a "main"
oncoprotein. In our study, HCC78R cells maintained ROS1 fusion genes ( Figure 1C ) but their RNA or protein expression decreased in HCC78R cells due to unknown mechanisms compared with that in parental HCC78R cells ( Figures 1D, S1C and Table S1 ). Furthermore, the dependency on ROS1 protein seems to be almost lost (Figures 1A, 2C and S4C ). Taken together, "oncogene swap" may have occurred in HCC78R cells. 
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